In addition, inhibition of the PI3K/Akt pathway enhanced the therapeutic efficacy of paclitaxel in GC cells under hypoxic conditions, suggesting that the PI3K/Akt or HIF-1α pathway may serve as an important therapeutic target for the paclitaxel treatment of cancer. The gene discussed is HIF1A; the disease is cancer.